img

Global Angiogenesis Therapeutic Agent Market Insights, Forecast to 2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Angiogenesis Therapeutic Agent Market Insights, Forecast to 2034

Anti-angiogenic ophthalmic agents act as antagonists against the vascular endothelial growth factor (VEGF). When retinal pigment cells become ischemic and dry up VEGF stimulates generation of new blood vessels by a process called neovascularization. If new blood vessels are not generated properly, leakage occurs in retina, which leads to vision loss. Angiogenesis plays an important role in chronic inflammation and fibrosis, tumor growth and vascularization of ischemic tissue.
Global Angiogenesis Therapeutic Agent market is expected to reach to US$ million in 2024, with a positive growth of %, compared with US$ million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Angiogenesis Therapeutic Agent industry is evaluated to reach US$ million in 2029. The CAGR will be % during 2024 to 2029.
Globally, Angiogenesis Therapeutic Agent key manufacturers include Gilead Sciences, Inc., Eyetech Inc., Becton, Dickinson and Company, Regeneron Pharmaceuticals, Inc., Genentech, Inc., Novartis AG, Allergan plc, Bayer AG and Santen Pharmaceutical Co., Ltd., etc. Gilead Sciences, Inc., Eyetech Inc., Becton, Dickinson and Company are top 3 players and held % sales share in total in 2022.
When considering the consumption regions, % volume of Angiogenesis Therapeutic Agent were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029 and the sales share will be % in 2029. Moreover, China, plays a key role in the whole Angiogenesis Therapeutic Agent market and estimated to attract more attentions from industry insiders and investors.
Angiogenesis Therapeutic Agent can be divided into Myopic Choroidal Neovascularization, Macular Edema, Diabetic Retinopathy and Macular Degeneration, etc. Myopic Choroidal Neovascularization is the mainstream product in the market, accounting for % sales share globally in 2022 and the proportion will be % in 2029.
Angiogenesis Therapeutic Agent is widely used in various fields, such as Retail Pharmacies, Online Pharmacies and Hospital Pharmacies,, etc. Retail Pharmacies provides greatest supports to the Angiogenesis Therapeutic Agent industry development. In 2022, global % sales of Angiogenesis Therapeutic Agent went into Retail Pharmacies filed and the proportion will reach to % in 2029.
Report Covers
This report presents an overview of global Angiogenesis Therapeutic Agent market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Angiogenesis Therapeutic Agent market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Gilead Sciences, Inc.
Eyetech Inc.
Becton, Dickinson and Company
Regeneron Pharmaceuticals, Inc.
Genentech, Inc.
Novartis AG
Allergan plc
Bayer AG
Santen Pharmaceutical Co., Ltd.
Shanghai Pharmaceuticals
Johnson & Johnson
Pfizer
Sun Pharma
Otsuka Pharmaceutical Co. Ltd
Daiichi Sankyo
ERC Labs
Medicom Health care
Implandata ophthalmic products GmbH
The Geuder Group, MORCHER GmbH
Novamedika
Segment by Type
Myopic Choroidal Neovascularization
Macular Edema
Diabetic Retinopathy
Macular Degeneration

Segment by Application


Retail Pharmacies
Online Pharmacies
Hospital Pharmacies

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Angiogenesis Therapeutic Agent plant distribution, commercial date of Angiogenesis Therapeutic Agent, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Angiogenesis Therapeutic Agent introduction, etc. Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports’s Conclusions of Angiogenesis Therapeutic Agent
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Study Coverage
1.1 Angiogenesis Therapeutic Agent Product Introduction
1.2 Market by Type
1.2.1 Global Angiogenesis Therapeutic Agent Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Myopic Choroidal Neovascularization
1.2.3 Macular Edema
1.2.4 Diabetic Retinopathy
1.2.5 Macular Degeneration
1.3 Market by Application
1.3.1 Global Angiogenesis Therapeutic Agent Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Retail Pharmacies
1.3.3 Online Pharmacies
1.3.4 Hospital Pharmacies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Angiogenesis Therapeutic Agent Sales Estimates and Forecasts 2018-2029
2.2 Global Angiogenesis Therapeutic Agent Revenue by Region
2.2.1 Global Angiogenesis Therapeutic Agent Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Angiogenesis Therapeutic Agent Revenue by Region (2018-2024)
2.2.3 Global Angiogenesis Therapeutic Agent Revenue by Region (2024-2029)
2.2.4 Global Angiogenesis Therapeutic Agent Revenue Market Share by Region (2018-2029)
2.3 Global Angiogenesis Therapeutic Agent Sales Estimates and Forecasts 2018-2029
2.4 Global Angiogenesis Therapeutic Agent Sales by Region
2.4.1 Global Angiogenesis Therapeutic Agent Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Angiogenesis Therapeutic Agent Sales by Region (2018-2024)
2.4.3 Global Angiogenesis Therapeutic Agent Sales by Region (2024-2029)
2.4.4 Global Angiogenesis Therapeutic Agent Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Angiogenesis Therapeutic Agent Sales by Manufacturers
3.1.1 Global Angiogenesis Therapeutic Agent Sales by Manufacturers (2018-2024)
3.1.2 Global Angiogenesis Therapeutic Agent Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Angiogenesis Therapeutic Agent in 2022
3.2 Global Angiogenesis Therapeutic Agent Revenue by Manufacturers
3.2.1 Global Angiogenesis Therapeutic Agent Revenue by Manufacturers (2018-2024)
3.2.2 Global Angiogenesis Therapeutic Agent Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Angiogenesis Therapeutic Agent Revenue in 2022
3.3 Global Key Players of Angiogenesis Therapeutic Agent, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Angiogenesis Therapeutic Agent Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Angiogenesis Therapeutic Agent Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Angiogenesis Therapeutic Agent, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Angiogenesis Therapeutic Agent, Product Offered and Application
3.8 Global Key Manufacturers of Angiogenesis Therapeutic Agent, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Angiogenesis Therapeutic Agent Sales by Type
4.1.1 Global Angiogenesis Therapeutic Agent Historical Sales by Type (2018-2024)
4.1.2 Global Angiogenesis Therapeutic Agent Forecasted Sales by Type (2024-2029)
4.1.3 Global Angiogenesis Therapeutic Agent Sales Market Share by Type (2018-2029)
4.2 Global Angiogenesis Therapeutic Agent Revenue by Type
4.2.1 Global Angiogenesis Therapeutic Agent Historical Revenue by Type (2018-2024)
4.2.2 Global Angiogenesis Therapeutic Agent Forecasted Revenue by Type (2024-2029)
4.2.3 Global Angiogenesis Therapeutic Agent Revenue Market Share by Type (2018-2029)
4.3 Global Angiogenesis Therapeutic Agent Price by Type
4.3.1 Global Angiogenesis Therapeutic Agent Price by Type (2018-2024)
4.3.2 Global Angiogenesis Therapeutic Agent Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Angiogenesis Therapeutic Agent Sales by Application
5.1.1 Global Angiogenesis Therapeutic Agent Historical Sales by Application (2018-2024)
5.1.2 Global Angiogenesis Therapeutic Agent Forecasted Sales by Application (2024-2029)
5.1.3 Global Angiogenesis Therapeutic Agent Sales Market Share by Application (2018-2029)
5.2 Global Angiogenesis Therapeutic Agent Revenue by Application
5.2.1 Global Angiogenesis Therapeutic Agent Historical Revenue by Application (2018-2024)
5.2.2 Global Angiogenesis Therapeutic Agent Forecasted Revenue by Application (2024-2029)
5.2.3 Global Angiogenesis Therapeutic Agent Revenue Market Share by Application (2018-2029)
5.3 Global Angiogenesis Therapeutic Agent Price by Application
5.3.1 Global Angiogenesis Therapeutic Agent Price by Application (2018-2024)
5.3.2 Global Angiogenesis Therapeutic Agent Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Angiogenesis Therapeutic Agent Market Size by Type
6.1.1 US & Canada Angiogenesis Therapeutic Agent Sales by Type (2018-2029)
6.1.2 US & Canada Angiogenesis Therapeutic Agent Revenue by Type (2018-2029)
6.2 US & Canada Angiogenesis Therapeutic Agent Market Size by Application
6.2.1 US & Canada Angiogenesis Therapeutic Agent Sales by Application (2018-2029)
6.2.2 US & Canada Angiogenesis Therapeutic Agent Revenue by Application (2018-2029)
6.3 US & Canada Angiogenesis Therapeutic Agent Market Size by Country
6.3.1 US & Canada Angiogenesis Therapeutic Agent Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Angiogenesis Therapeutic Agent Sales by Country (2018-2029)
6.3.3 US & Canada Angiogenesis Therapeutic Agent Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Angiogenesis Therapeutic Agent Market Size by Type
7.1.1 Europe Angiogenesis Therapeutic Agent Sales by Type (2018-2029)
7.1.2 Europe Angiogenesis Therapeutic Agent Revenue by Type (2018-2029)
7.2 Europe Angiogenesis Therapeutic Agent Market Size by Application
7.2.1 Europe Angiogenesis Therapeutic Agent Sales by Application (2018-2029)
7.2.2 Europe Angiogenesis Therapeutic Agent Revenue by Application (2018-2029)
7.3 Europe Angiogenesis Therapeutic Agent Market Size by Country
7.3.1 Europe Angiogenesis Therapeutic Agent Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Angiogenesis Therapeutic Agent Sales by Country (2018-2029)
7.3.3 Europe Angiogenesis Therapeutic Agent Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Angiogenesis Therapeutic Agent Market Size
8.1.1 China Angiogenesis Therapeutic Agent Sales (2018-2029)
8.1.2 China Angiogenesis Therapeutic Agent Revenue (2018-2029)
8.2 China Angiogenesis Therapeutic Agent Market Size by Application
8.2.1 China Angiogenesis Therapeutic Agent Sales by Application (2018-2029)
8.2.2 China Angiogenesis Therapeutic Agent Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Angiogenesis Therapeutic Agent Market Size by Type
9.1.1 Asia Angiogenesis Therapeutic Agent Sales by Type (2018-2029)
9.1.2 Asia Angiogenesis Therapeutic Agent Revenue by Type (2018-2029)
9.2 Asia Angiogenesis Therapeutic Agent Market Size by Application
9.2.1 Asia Angiogenesis Therapeutic Agent Sales by Application (2018-2029)
9.2.2 Asia Angiogenesis Therapeutic Agent Revenue by Application (2018-2029)
9.3 Asia Angiogenesis Therapeutic Agent Sales by Region
9.3.1 Asia Angiogenesis Therapeutic Agent Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Angiogenesis Therapeutic Agent Revenue by Region (2018-2029)
9.3.3 Asia Angiogenesis Therapeutic Agent Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Angiogenesis Therapeutic Agent Market Size by Type
10.1.1 Middle East, Africa and Latin America Angiogenesis Therapeutic Agent Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Angiogenesis Therapeutic Agent Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Angiogenesis Therapeutic Agent Market Size by Application
10.2.1 Middle East, Africa and Latin America Angiogenesis Therapeutic Agent Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Angiogenesis Therapeutic Agent Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Angiogenesis Therapeutic Agent Sales by Country
10.3.1 Middle East, Africa and Latin America Angiogenesis Therapeutic Agent Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Angiogenesis Therapeutic Agent Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Angiogenesis Therapeutic Agent Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Gilead Sciences, Inc.
11.1.1 Gilead Sciences, Inc. Company Information
11.1.2 Gilead Sciences, Inc. Overview
11.1.3 Gilead Sciences, Inc. Angiogenesis Therapeutic Agent Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Gilead Sciences, Inc. Angiogenesis Therapeutic Agent Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Gilead Sciences, Inc. Recent Developments
11.2 Eyetech Inc.
11.2.1 Eyetech Inc. Company Information
11.2.2 Eyetech Inc. Overview
11.2.3 Eyetech Inc. Angiogenesis Therapeutic Agent Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 Eyetech Inc. Angiogenesis Therapeutic Agent Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Eyetech Inc. Recent Developments
11.3 Becton, Dickinson and Company
11.3.1 Becton, Dickinson and Company Company Information
11.3.2 Becton, Dickinson and Company Overview
11.3.3 Becton, Dickinson and Company Angiogenesis Therapeutic Agent Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Becton, Dickinson and Company Angiogenesis Therapeutic Agent Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Becton, Dickinson and Company Recent Developments
11.4 Regeneron Pharmaceuticals, Inc.
11.4.1 Regeneron Pharmaceuticals, Inc. Company Information
11.4.2 Regeneron Pharmaceuticals, Inc. Overview
11.4.3 Regeneron Pharmaceuticals, Inc. Angiogenesis Therapeutic Agent Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Regeneron Pharmaceuticals, Inc. Angiogenesis Therapeutic Agent Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Regeneron Pharmaceuticals, Inc. Recent Developments
11.5 Genentech, Inc.
11.5.1 Genentech, Inc. Company Information
11.5.2 Genentech, Inc. Overview
11.5.3 Genentech, Inc. Angiogenesis Therapeutic Agent Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 Genentech, Inc. Angiogenesis Therapeutic Agent Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Genentech, Inc. Recent Developments
11.6 Novartis AG
11.6.1 Novartis AG Company Information
11.6.2 Novartis AG Overview
11.6.3 Novartis AG Angiogenesis Therapeutic Agent Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 Novartis AG Angiogenesis Therapeutic Agent Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Novartis AG Recent Developments
11.7 Allergan plc
11.7.1 Allergan plc Company Information
11.7.2 Allergan plc Overview
11.7.3 Allergan plc Angiogenesis Therapeutic Agent Sales, Price, Revenue and Gross Margin (2018-2024)
11.7.4 Allergan plc Angiogenesis Therapeutic Agent Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Allergan plc Recent Developments
11.8 Bayer AG
11.8.1 Bayer AG Company Information
11.8.2 Bayer AG Overview
11.8.3 Bayer AG Angiogenesis Therapeutic Agent Sales, Price, Revenue and Gross Margin (2018-2024)
11.8.4 Bayer AG Angiogenesis Therapeutic Agent Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Bayer AG Recent Developments
11.9 Santen Pharmaceutical Co., Ltd.
11.9.1 Santen Pharmaceutical Co., Ltd. Company Information
11.9.2 Santen Pharmaceutical Co., Ltd. Overview
11.9.3 Santen Pharmaceutical Co., Ltd. Angiogenesis Therapeutic Agent Sales, Price, Revenue and Gross Margin (2018-2024)
11.9.4 Santen Pharmaceutical Co., Ltd. Angiogenesis Therapeutic Agent Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Santen Pharmaceutical Co., Ltd. Recent Developments
11.10 Shanghai Pharmaceuticals
11.10.1 Shanghai Pharmaceuticals Company Information
11.10.2 Shanghai Pharmaceuticals Overview
11.10.3 Shanghai Pharmaceuticals Angiogenesis Therapeutic Agent Sales, Price, Revenue and Gross Margin (2018-2024)
11.10.4 Shanghai Pharmaceuticals Angiogenesis Therapeutic Agent Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Shanghai Pharmaceuticals Recent Developments
11.11 Johnson & Johnson
11.11.1 Johnson & Johnson Company Information
11.11.2 Johnson & Johnson Overview
11.11.3 Johnson & Johnson Angiogenesis Therapeutic Agent Sales, Price, Revenue and Gross Margin (2018-2024)
11.11.4 Johnson & Johnson Angiogenesis Therapeutic Agent Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Johnson & Johnson Recent Developments
11.12 Pfizer
11.12.1 Pfizer Company Information
11.12.2 Pfizer Overview
11.12.3 Pfizer Angiogenesis Therapeutic Agent Sales, Price, Revenue and Gross Margin (2018-2024)
11.12.4 Pfizer Angiogenesis Therapeutic Agent Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Pfizer Recent Developments
11.13 Sun Pharma
11.13.1 Sun Pharma Company Information
11.13.2 Sun Pharma Overview
11.13.3 Sun Pharma Angiogenesis Therapeutic Agent Sales, Price, Revenue and Gross Margin (2018-2024)
11.13.4 Sun Pharma Angiogenesis Therapeutic Agent Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Sun Pharma Recent Developments
11.14 Otsuka Pharmaceutical Co. Ltd
11.14.1 Otsuka Pharmaceutical Co. Ltd Company Information
11.14.2 Otsuka Pharmaceutical Co. Ltd Overview
11.14.3 Otsuka Pharmaceutical Co. Ltd Angiogenesis Therapeutic Agent Sales, Price, Revenue and Gross Margin (2018-2024)
11.14.4 Otsuka Pharmaceutical Co. Ltd Angiogenesis Therapeutic Agent Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Otsuka Pharmaceutical Co. Ltd Recent Developments
11.15 Daiichi Sankyo
11.15.1 Daiichi Sankyo Company Information
11.15.2 Daiichi Sankyo Overview
11.15.3 Daiichi Sankyo Angiogenesis Therapeutic Agent Sales, Price, Revenue and Gross Margin (2018-2024)
11.15.4 Daiichi Sankyo Angiogenesis Therapeutic Agent Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Daiichi Sankyo Recent Developments
11.16 ERC Labs
11.16.1 ERC Labs Company Information
11.16.2 ERC Labs Overview
11.16.3 ERC Labs Angiogenesis Therapeutic Agent Sales, Price, Revenue and Gross Margin (2018-2024)
11.16.4 ERC Labs Angiogenesis Therapeutic Agent Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 ERC Labs Recent Developments
11.17 Medicom Health care
11.17.1 Medicom Health care Company Information
11.17.2 Medicom Health care Overview
11.17.3 Medicom Health care Angiogenesis Therapeutic Agent Sales, Price, Revenue and Gross Margin (2018-2024)
11.17.4 Medicom Health care Angiogenesis Therapeutic Agent Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 Medicom Health care Recent Developments
11.18 Implandata ophthalmic products GmbH
11.18.1 Implandata ophthalmic products GmbH Company Information
11.18.2 Implandata ophthalmic products GmbH Overview
11.18.3 Implandata ophthalmic products GmbH Angiogenesis Therapeutic Agent Sales, Price, Revenue and Gross Margin (2018-2024)
11.18.4 Implandata ophthalmic products GmbH Angiogenesis Therapeutic Agent Product Model Numbers, Pictures, Descriptions and Specifications
11.18.5 Implandata ophthalmic products GmbH Recent Developments
11.19 The Geuder Group, MORCHER GmbH
11.19.1 The Geuder Group, MORCHER GmbH Company Information
11.19.2 The Geuder Group, MORCHER GmbH Overview
11.19.3 The Geuder Group, MORCHER GmbH Angiogenesis Therapeutic Agent Sales, Price, Revenue and Gross Margin (2018-2024)
11.19.4 The Geuder Group, MORCHER GmbH Angiogenesis Therapeutic Agent Product Model Numbers, Pictures, Descriptions and Specifications
11.19.5 The Geuder Group, MORCHER GmbH Recent Developments
11.20 Novamedika
11.20.1 Novamedika Company Information
11.20.2 Novamedika Overview
11.20.3 Novamedika Angiogenesis Therapeutic Agent Sales, Price, Revenue and Gross Margin (2018-2024)
11.20.4 Novamedika Angiogenesis Therapeutic Agent Product Model Numbers, Pictures, Descriptions and Specifications
11.20.5 Novamedika Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Angiogenesis Therapeutic Agent Industry Chain Analysis
12.2 Angiogenesis Therapeutic Agent Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Angiogenesis Therapeutic Agent Production Mode & Process
12.4 Angiogenesis Therapeutic Agent Sales and Marketing
12.4.1 Angiogenesis Therapeutic Agent Sales Channels
12.4.2 Angiogenesis Therapeutic Agent Distributors
12.5 Angiogenesis Therapeutic Agent Customers
13 Market Dynamics
13.1 Angiogenesis Therapeutic Agent Industry Trends
13.2 Angiogenesis Therapeutic Agent Market Drivers
13.3 Angiogenesis Therapeutic Agent Market Challenges
13.4 Angiogenesis Therapeutic Agent Market Restraints
14 Key Findings in The Global Angiogenesis Therapeutic Agent Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Angiogenesis Therapeutic Agent Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of Myopic Choroidal Neovascularization
Table 3. Major Manufacturers of Macular Edema
Table 4. Major Manufacturers of Diabetic Retinopathy
Table 5. Major Manufacturers of Macular Degeneration
Table 6. Global Angiogenesis Therapeutic Agent Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 7. Global Angiogenesis Therapeutic Agent Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 8. Global Angiogenesis Therapeutic Agent Revenue by Region (2018-2024) & (US$ Million)
Table 9. Global Angiogenesis Therapeutic Agent Revenue by Region (2024-2029) & (US$ Million)
Table 10. Global Angiogenesis Therapeutic Agent Revenue Market Share by Region (2018-2024)
Table 11. Global Angiogenesis Therapeutic Agent Revenue Market Share by Region (2024-2029)
Table 12. Global Angiogenesis Therapeutic Agent Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 13. Global Angiogenesis Therapeutic Agent Sales by Region (2018-2024) & (K Units)
Table 14. Global Angiogenesis Therapeutic Agent Sales by Region (2024-2029) & (K Units)
Table 15. Global Angiogenesis Therapeutic Agent Sales Market Share by Region (2018-2024)
Table 16. Global Angiogenesis Therapeutic Agent Sales Market Share by Region (2024-2029)
Table 17. Global Angiogenesis Therapeutic Agent Sales by Manufacturers (2018-2024) & (K Units)
Table 18. Global Angiogenesis Therapeutic Agent Sales Share by Manufacturers (2018-2024)
Table 19. Global Angiogenesis Therapeutic Agent Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 20. Global Angiogenesis Therapeutic Agent Revenue Share by Manufacturers (2018-2024)
Table 21. Global Key Players of Angiogenesis Therapeutic Agent, Industry Ranking, 2021 VS 2022 VS 2024
Table 22. Angiogenesis Therapeutic Agent Price by Manufacturers 2018-2024 (US$/Unit)
Table 23. Global Angiogenesis Therapeutic Agent Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 24. Global Angiogenesis Therapeutic Agent by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Angiogenesis Therapeutic Agent as of 2022)
Table 25. Global Key Manufacturers of Angiogenesis Therapeutic Agent, Manufacturing Base Distribution and Headquarters
Table 26. Global Key Manufacturers of Angiogenesis Therapeutic Agent, Product Offered and Application
Table 27. Global Key Manufacturers of Angiogenesis Therapeutic Agent, Date of Enter into This Industry
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Angiogenesis Therapeutic Agent Sales by Type (2018-2024) & (K Units)
Table 30. Global Angiogenesis Therapeutic Agent Sales by Type (2024-2029) & (K Units)
Table 31. Global Angiogenesis Therapeutic Agent Sales Share by Type (2018-2024)
Table 32. Global Angiogenesis Therapeutic Agent Sales Share by Type (2024-2029)
Table 33. Global Angiogenesis Therapeutic Agent Revenue by Type (2018-2024) & (US$ Million)
Table 34. Global Angiogenesis Therapeutic Agent Revenue by Type (2024-2029) & (US$ Million)
Table 35. Global Angiogenesis Therapeutic Agent Revenue Share by Type (2018-2024)
Table 36. Global Angiogenesis Therapeutic Agent Revenue Share by Type (2024-2029)
Table 37. Angiogenesis Therapeutic Agent Price by Type (2018-2024) & (US$/Unit)
Table 38. Global Angiogenesis Therapeutic Agent Price Forecast by Type (2024-2029) & (US$/Unit)
Table 39. Global Angiogenesis Therapeutic Agent Sales by Application (2018-2024) & (K Units)
Table 40. Global Angiogenesis Therapeutic Agent Sales by Application (2024-2029) & (K Units)
Table 41. Global Angiogenesis Therapeutic Agent Sales Share by Application (2018-2024)
Table 42. Global Angiogenesis Therapeutic Agent Sales Share by Application (2024-2029)
Table 43. Global Angiogenesis Therapeutic Agent Revenue by Application (2018-2024) & (US$ Million)
Table 44. Global Angiogenesis Therapeutic Agent Revenue by Application (2024-2029) & (US$ Million)
Table 45. Global Angiogenesis Therapeutic Agent Revenue Share by Application (2018-2024)
Table 46. Global Angiogenesis Therapeutic Agent Revenue Share by Application (2024-2029)
Table 47. Angiogenesis Therapeutic Agent Price by Application (2018-2024) & (US$/Unit)
Table 48. Global Angiogenesis Therapeutic Agent Price Forecast by Application (2024-2029) & (US$/Unit)
Table 49. US & Canada Angiogenesis Therapeutic Agent Sales by Type (2018-2024) & (K Units)
Table 50. US & Canada Angiogenesis Therapeutic Agent Sales by Type (2024-2029) & (K Units)
Table 51. US & Canada Angiogenesis Therapeutic Agent Revenue by Type (2018-2024) & (US$ Million)
Table 52. US & Canada Angiogenesis Therapeutic Agent Revenue by Type (2024-2029) & (US$ Million)
Table 53. US & Canada Angiogenesis Therapeutic Agent Sales by Application (2018-2024) & (K Units)
Table 54. US & Canada Angiogenesis Therapeutic Agent Sales by Application (2024-2029) & (K Units)
Table 55. US & Canada Angiogenesis Therapeutic Agent Revenue by Application (2018-2024) & (US$ Million)
Table 56. US & Canada Angiogenesis Therapeutic Agent Revenue by Application (2024-2029) & (US$ Million)
Table 57. US & Canada Angiogenesis Therapeutic Agent Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 58. US & Canada Angiogenesis Therapeutic Agent Revenue by Country (2018-2024) & (US$ Million)
Table 59. US & Canada Angiogenesis Therapeutic Agent Revenue by Country (2024-2029) & (US$ Million)
Table 60. US & Canada Angiogenesis Therapeutic Agent Sales by Country (2018-2024) & (K Units)
Table 61. US & Canada Angiogenesis Therapeutic Agent Sales by Country (2024-2029) & (K Units)
Table 62. Europe Angiogenesis Therapeutic Agent Sales by Type (2018-2024) & (K Units)
Table 63. Europe Angiogenesis Therapeutic Agent Sales by Type (2024-2029) & (K Units)
Table 64. Europe Angiogenesis Therapeutic Agent Revenue by Type (2018-2024) & (US$ Million)
Table 65. Europe Angiogenesis Therapeutic Agent Revenue by Type (2024-2029) & (US$ Million)
Table 66. Europe Angiogenesis Therapeutic Agent Sales by Application (2018-2024) & (K Units)
Table 67. Europe Angiogenesis Therapeutic Agent Sales by Application (2024-2029) & (K Units)
Table 68. Europe Angiogenesis Therapeutic Agent Revenue by Application (2018-2024) & (US$ Million)
Table 69. Europe Angiogenesis Therapeutic Agent Revenue by Application (2024-2029) & (US$ Million)
Table 70. Europe Angiogenesis Therapeutic Agent Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 71. Europe Angiogenesis Therapeutic Agent Revenue by Country (2018-2024) & (US$ Million)
Table 72. Europe Angiogenesis Therapeutic Agent Revenue by Country (2024-2029) & (US$ Million)
Table 73. Europe Angiogenesis Therapeutic Agent Sales by Country (2018-2024) & (K Units)
Table 74. Europe Angiogenesis Therapeutic Agent Sales by Country (2024-2029) & (K Units)
Table 75. China Angiogenesis Therapeutic Agent Sales by Type (2018-2024) & (K Units)
Table 76. China Angiogenesis Therapeutic Agent Sales by Type (2024-2029) & (K Units)
Table 77. China Angiogenesis Therapeutic Agent Revenue by Type (2018-2024) & (US$ Million)
Table 78. China Angiogenesis Therapeutic Agent Revenue by Type (2024-2029) & (US$ Million)
Table 79. China Angiogenesis Therapeutic Agent Sales by Application (2018-2024) & (K Units)
Table 80. China Angiogenesis Therapeutic Agent Sales by Application (2024-2029) & (K Units)
Table 81. China Angiogenesis Therapeutic Agent Revenue by Application (2018-2024) & (US$ Million)
Table 82. China Angiogenesis Therapeutic Agent Revenue by Application (2024-2029) & (US$ Million)
Table 83. Asia Angiogenesis Therapeutic Agent Sales by Type (2018-2024) & (K Units)
Table 84. Asia Angiogenesis Therapeutic Agent Sales by Type (2024-2029) & (K Units)
Table 85. Asia Angiogenesis Therapeutic Agent Revenue by Type (2018-2024) & (US$ Million)
Table 86. Asia Angiogenesis Therapeutic Agent Revenue by Type (2024-2029) & (US$ Million)
Table 87. Asia Angiogenesis Therapeutic Agent Sales by Application (2018-2024) & (K Units)
Table 88. Asia Angiogenesis Therapeutic Agent Sales by Application (2024-2029) & (K Units)
Table 89. Asia Angiogenesis Therapeutic Agent Revenue by Application (2018-2024) & (US$ Million)
Table 90. Asia Angiogenesis Therapeutic Agent Revenue by Application (2024-2029) & (US$ Million)
Table 91. Asia Angiogenesis Therapeutic Agent Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 92. Asia Angiogenesis Therapeutic Agent Revenue by Region (2018-2024) & (US$ Million)
Table 93. Asia Angiogenesis Therapeutic Agent Revenue by Region (2024-2029) & (US$ Million)
Table 94. Asia Angiogenesis Therapeutic Agent Sales by Region (2018-2024) & (K Units)
Table 95. Asia Angiogenesis Therapeutic Agent Sales by Region (2024-2029) & (K Units)
Table 96. Middle East, Africa and Latin America Angiogenesis Therapeutic Agent Sales by Type (2018-2024) & (K Units)
Table 97. Middle East, Africa and Latin America Angiogenesis Therapeutic Agent Sales by Type (2024-2029) & (K Units)
Table 98. Middle East, Africa and Latin America Angiogenesis Therapeutic Agent Revenue by Type (2018-2024) & (US$ Million)
Table 99. Middle East, Africa and Latin America Angiogenesis Therapeutic Agent Revenue by Type (2024-2029) & (US$ Million)
Table 100. Middle East, Africa and Latin America Angiogenesis Therapeutic Agent Sales by Application (2018-2024) & (K Units)
Table 101. Middle East, Africa and Latin America Angiogenesis Therapeutic Agent Sales by Application (2024-2029) & (K Units)
Table 102. Middle East, Africa and Latin America Angiogenesis Therapeutic Agent Revenue by Application (2018-2024) & (US$ Million)
Table 103. Middle East, Africa and Latin America Angiogenesis Therapeutic Agent Revenue by Application (2024-2029) & (US$ Million)
Table 104. Middle East, Africa and Latin America Angiogenesis Therapeutic Agent Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 105. Middle East, Africa and Latin America Angiogenesis Therapeutic Agent Revenue by Country (2018-2024) & (US$ Million)
Table 106. Middle East, Africa and Latin America Angiogenesis Therapeutic Agent Revenue by Country (2024-2029) & (US$ Million)
Table 107. Middle East, Africa and Latin America Angiogenesis Therapeutic Agent Sales by Country (2018-2024) & (K Units)
Table 108. Middle East, Africa and Latin America Angiogenesis Therapeutic Agent Sales by Country (2024-2029) & (K Units)
Table 109. Gilead Sciences, Inc. Company Information
Table 110. Gilead Sciences, Inc. Description and Major Businesses
Table 111. Gilead Sciences, Inc. Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 112. Gilead Sciences, Inc. Angiogenesis Therapeutic Agent Product Model Numbers, Pictures, Descriptions and Specifications
Table 113. Gilead Sciences, Inc. Recent Developments
Table 114. Eyetech Inc. Company Information
Table 115. Eyetech Inc. Description and Major Businesses
Table 116. Eyetech Inc. Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 117. Eyetech Inc. Angiogenesis Therapeutic Agent Product Model Numbers, Pictures, Descriptions and Specifications
Table 118. Eyetech Inc. Recent Developments
Table 119. Becton, Dickinson and Company Company Information
Table 120. Becton, Dickinson and Company Description and Major Businesses
Table 121. Becton, Dickinson and Company Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 122. Becton, Dickinson and Company Angiogenesis Therapeutic Agent Product Model Numbers, Pictures, Descriptions and Specifications
Table 123. Becton, Dickinson and Company Recent Developments
Table 124. Regeneron Pharmaceuticals, Inc. Company Information
Table 125. Regeneron Pharmaceuticals, Inc. Description and Major Businesses
Table 126. Regeneron Pharmaceuticals, Inc. Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 127. Regeneron Pharmaceuticals, Inc. Angiogenesis Therapeutic Agent Product Model Numbers, Pictures, Descriptions and Specifications
Table 128. Regeneron Pharmaceuticals, Inc. Recent Developments
Table 129. Genentech, Inc. Company Information
Table 130. Genentech, Inc. Description and Major Businesses
Table 131. Genentech, Inc. Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 132. Genentech, Inc. Angiogenesis Therapeutic Agent Product Model Numbers, Pictures, Descriptions and Specifications
Table 133. Genentech, Inc. Recent Developments
Table 134. Novartis AG Company Information
Table 135. Novartis AG Description and Major Businesses
Table 136. Novartis AG Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 137. Novartis AG Angiogenesis Therapeutic Agent Product Model Numbers, Pictures, Descriptions and Specifications
Table 138. Novartis AG Recent Developments
Table 139. Allergan plc Company Information
Table 140. Allergan plc Description and Major Businesses
Table 141. Allergan plc Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 142. Allergan plc Angiogenesis Therapeutic Agent Product Model Numbers, Pictures, Descriptions and Specifications
Table 143. Allergan plc Recent Developments
Table 144. Bayer AG Company Information
Table 145. Bayer AG Description and Major Businesses
Table 146. Bayer AG Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 147. Bayer AG Angiogenesis Therapeutic Agent Product Model Numbers, Pictures, Descriptions and Specifications
Table 148. Bayer AG Recent Developments
Table 149. Santen Pharmaceutical Co., Ltd. Company Information
Table 150. Santen Pharmaceutical Co., Ltd. Description and Major Businesses
Table 151. Santen Pharmaceutical Co., Ltd. Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 152. Santen Pharmaceutical Co., Ltd. Angiogenesis Therapeutic Agent Product Model Numbers, Pictures, Descriptions and Specifications
Table 153. Santen Pharmaceutical Co., Ltd. Recent Developments
Table 154. Shanghai Pharmaceuticals Company Information
Table 155. Shanghai Pharmaceuticals Description and Major Businesses
Table 156. Shanghai Pharmaceuticals Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 157. Shanghai Pharmaceuticals Angiogenesis Therapeutic Agent Product Model Numbers, Pictures, Descriptions and Specifications
Table 158. Shanghai Pharmaceuticals Recent Developments
Table 159. Johnson & Johnson Company Information
Table 160. Johnson & Johnson Description and Major Businesses
Table 161. Johnson & Johnson Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 162. Johnson & Johnson Angiogenesis Therapeutic Agent Product Model Numbers, Pictures, Descriptions and Specifications
Table 163. Johnson & Johnson Recent Developments
Table 164. Pfizer Company Information
Table 165. Pfizer Description and Major Businesses
Table 166. Pfizer Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 167. Pfizer Angiogenesis Therapeutic Agent Product Model Numbers, Pictures, Descriptions and Specifications
Table 168. Pfizer Recent Developments
Table 169. Sun Pharma Company Information
Table 170. Sun Pharma Description and Major Businesses
Table 171. Sun Pharma Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 172. Sun Pharma Angiogenesis Therapeutic Agent Product Model Numbers, Pictures, Descriptions and Specifications
Table 173. Sun Pharma Recent Developments
Table 174. Otsuka Pharmaceutical Co. Ltd Company Information
Table 175. Otsuka Pharmaceutical Co. Ltd Description and Major Businesses
Table 176. Otsuka Pharmaceutical Co. Ltd Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 177. Otsuka Pharmaceutical Co. Ltd Angiogenesis Therapeutic Agent Product Model Numbers, Pictures, Descriptions and Specifications
Table 178. Otsuka Pharmaceutical Co. Ltd Recent Developments
Table 179. Daiichi Sankyo Company Information
Table 180. Daiichi Sankyo Description and Major Businesses
Table 181. Daiichi Sankyo Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 182. Daiichi Sankyo Angiogenesis Therapeutic Agent Product Model Numbers, Pictures, Descriptions and Specifications
Table 183. Daiichi Sankyo Recent Developments
Table 184. ERC Labs Company Information
Table 185. ERC Labs Description and Major Businesses
Table 186. ERC Labs Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 187. ERC Labs Angiogenesis Therapeutic Agent Product Model Numbers, Pictures, Descriptions and Specifications
Table 188. ERC Labs Recent Developments
Table 189. Medicom Health care Company Information
Table 190. Medicom Health care Description and Major Businesses
Table 191. Medicom Health care Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 192. Medicom Health care Angiogenesis Therapeutic Agent Product Model Numbers, Pictures, Descriptions and Specifications
Table 193. Medicom Health care Recent Developments
Table 194. Implandata ophthalmic products GmbH Company Information
Table 195. Implandata ophthalmic products GmbH Description and Major Businesses
Table 196. Implandata ophthalmic products GmbH Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 197. Implandata ophthalmic products GmbH Angiogenesis Therapeutic Agent Product Model Numbers, Pictures, Descriptions and Specifications
Table 198. Implandata ophthalmic products GmbH Recent Developments
Table 199. The Geuder Group, MORCHER GmbH Company Information
Table 200. The Geuder Group, MORCHER GmbH Description and Major Businesses
Table 201. The Geuder Group, MORCHER GmbH Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 202. The Geuder Group, MORCHER GmbH Angiogenesis Therapeutic Agent Product Model Numbers, Pictures, Descriptions and Specifications
Table 203. The Geuder Group, MORCHER GmbH Recent Developments
Table 204. Novamedika Company Information
Table 205. Novamedika Description and Major Businesses
Table 206. Novamedika Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 207. Novamedika Angiogenesis Therapeutic Agent Product Model Numbers, Pictures, Descriptions and Specifications
Table 208. Novamedika Recent Developments
Table 209. Key Raw Materials Lists
Table 210. Raw Materials Key Suppliers Lists
Table 211. Angiogenesis Therapeutic Agent Distributors List
Table 212. Angiogenesis Therapeutic Agent Customers List
Table 213. Angiogenesis Therapeutic Agent Market Trends
Table 214. Angiogenesis Therapeutic Agent Market Drivers
Table 215. Angiogenesis Therapeutic Agent Market Challenges
Table 216. Angiogenesis Therapeutic Agent Market Restraints
Table 217. Research Programs/Design for This Report
Table 218. Key Data Information from Secondary Sources
Table 219. Key Data Information from Primary Sources
List of Figures
Figure 1. Angiogenesis Therapeutic Agent Product Picture
Figure 2. Global Angiogenesis Therapeutic Agent Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Angiogenesis Therapeutic Agent Market Share by Type in 2022 & 2029
Figure 4. Myopic Choroidal Neovascularization Product Picture
Figure 5. Macular Edema Product Picture
Figure 6. Diabetic Retinopathy Product Picture
Figure 7. Macular Degeneration Product Picture
Figure 8. Global Angiogenesis Therapeutic Agent Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 9. Global Angiogenesis Therapeutic Agent Market Share by Application in 2022 & 2029
Figure 10. Retail Pharmacies
Figure 11. Online Pharmacies
Figure 12. Hospital Pharmacies
Figure 13. Angiogenesis Therapeutic Agent Report Years Considered
Figure 14. Global Angiogenesis Therapeutic Agent Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 15. Global Angiogenesis Therapeutic Agent Revenue 2018-2029 (US$ Million)
Figure 16. Global Angiogenesis Therapeutic Agent Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 17. Global Angiogenesis Therapeutic Agent Revenue Market Share by Region (2018-2029)
Figure 18. Global Angiogenesis Therapeutic Agent Sales 2018-2029 ((K Units)
Figure 19. Global Angiogenesis Therapeutic Agent Sales Market Share by Region (2018-2029)
Figure 20. US & Canada Angiogenesis Therapeutic Agent Sales YoY (2018-2029) & (K Units)
Figure 21. US & Canada Angiogenesis Therapeutic Agent Revenue YoY (2018-2029) & (US$ Million)
Figure 22. Europe Angiogenesis Therapeutic Agent Sales YoY (2018-2029) & (K Units)
Figure 23. Europe Angiogenesis Therapeutic Agent Revenue YoY (2018-2029) & (US$ Million)
Figure 24. China Angiogenesis Therapeutic Agent Sales YoY (2018-2029) & (K Units)
Figure 25. China Angiogenesis Therapeutic Agent Revenue YoY (2018-2029) & (US$ Million)
Figure 26. Asia (excluding China) Angiogenesis Therapeutic Agent Sales YoY (2018-2029) & (K Units)
Figure 27. Asia (excluding China) Angiogenesis Therapeutic Agent Revenue YoY (2018-2029) & (US$ Million)
Figure 28. Middle East, Africa and Latin America Angiogenesis Therapeutic Agent Sales YoY (2018-2029) & (K Units)
Figure 29. Middle East, Africa and Latin America Angiogenesis Therapeutic Agent Revenue YoY (2018-2029) & (US$ Million)
Figure 30. The Angiogenesis Therapeutic Agent Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 31. The Top 5 and 10 Largest Manufacturers of Angiogenesis Therapeutic Agent in the World: Market Share by Angiogenesis Therapeutic Agent Revenue in 2022
Figure 32. Global Angiogenesis Therapeutic Agent Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 33. Global Angiogenesis Therapeutic Agent Sales Market Share by Type (2018-2029)
Figure 34. Global Angiogenesis Therapeutic Agent Revenue Market Share by Type (2018-2029)
Figure 35. Global Angiogenesis Therapeutic Agent Sales Market Share by Application (2018-2029)
Figure 36. Global Angiogenesis Therapeutic Agent Revenue Market Share by Application (2018-2029)
Figure 37. US & Canada Angiogenesis Therapeutic Agent Sales Market Share by Type (2018-2029)
Figure 38. US & Canada Angiogenesis Therapeutic Agent Revenue Market Share by Type (2018-2029)
Figure 39. US & Canada Angiogenesis Therapeutic Agent Sales Market Share by Application (2018-2029)
Figure 40. US & Canada Angiogenesis Therapeutic Agent Revenue Market Share by Application (2018-2029)
Figure 41. US & Canada Angiogenesis Therapeutic Agent Revenue Share by Country (2018-2029)
Figure 42. US & Canada Angiogenesis Therapeutic Agent Sales Share by Country (2018-2029)
Figure 43. U.S. Angiogenesis Therapeutic Agent Revenue (2018-2029) & (US$ Million)
Figure 44. Canada Angiogenesis Therapeutic Agent Revenue (2018-2029) & (US$ Million)
Figure 45. Europe Angiogenesis Therapeutic Agent Sales Market Share by Type (2018-2029)
Figure 46. Europe Angiogenesis Therapeutic Agent Revenue Market Share by Type (2018-2029)
Figure 47. Europe Angiogenesis Therapeutic Agent Sales Market Share by Application (2018-2029)
Figure 48. Europe Angiogenesis Therapeutic Agent Revenue Market Share by Application (2018-2029)
Figure 49. Europe Angiogenesis Therapeutic Agent Revenue Share by Country (2018-2029)
Figure 50. Europe Angiogenesis Therapeutic Agent Sales Share by Country (2018-2029)
Figure 51. Germany Angiogenesis Therapeutic Agent Revenue (2018-2029) & (US$ Million)
Figure 52. France Angiogenesis Therapeutic Agent Revenue (2018-2029) & (US$ Million)
Figure 53. U.K. Angiogenesis Therapeutic Agent Revenue (2018-2029) & (US$ Million)
Figure 54. Italy Angiogenesis Therapeutic Agent Revenue (2018-2029) & (US$ Million)
Figure 55. Russia Angiogenesis Therapeutic Agent Revenue (2018-2029) & (US$ Million)
Figure 56. China Angiogenesis Therapeutic Agent Sales Market Share by Type (2018-2029)
Figure 57. China Angiogenesis Therapeutic Agent Revenue Market Share by Type (2018-2029)
Figure 58. China Angiogenesis Therapeutic Agent Sales Market Share by Application (2018-2029)
Figure 59. China Angiogenesis Therapeutic Agent Revenue Market Share by Application (2018-2029)
Figure 60. Asia Angiogenesis Therapeutic Agent Sales Market Share by Type (2018-2029)
Figure 61. Asia Angiogenesis Therapeutic Agent Revenue Market Share by Type (2018-2029)
Figure 62. Asia Angiogenesis Therapeutic Agent Sales Market Share by Application (2018-2029)
Figure 63. Asia Angiogenesis Therapeutic Agent Revenue Market Share by Application (2018-2029)
Figure 64. Asia Angiogenesis Therapeutic Agent Revenue Share by Region (2018-2029)
Figure 65. Asia Angiogenesis Therapeutic Agent Sales Share by Region (2018-2029)
Figure 66. Japan Angiogenesis Therapeutic Agent Revenue (2018-2029) & (US$ Million)
Figure 67. South Korea Angiogenesis Therapeutic Agent Revenue (2018-2029) & (US$ Million)
Figure 68. China Taiwan Angiogenesis Therapeutic Agent Revenue (2018-2029) & (US$ Million)
Figure 69. Southeast Asia Angiogenesis Therapeutic Agent Revenue (2018-2029) & (US$ Million)
Figure 70. India Angiogenesis Therapeutic Agent Revenue (2018-2029) & (US$ Million)
Figure 71. Middle East, Africa and Latin America Angiogenesis Therapeutic Agent Sales Market Share by Type (2018-2029)
Figure 72. Middle East, Africa and Latin America Angiogenesis Therapeutic Agent Revenue Market Share by Type (2018-2029)
Figure 73. Middle East, Africa and Latin America Angiogenesis Therapeutic Agent Sales Market Share by Application (2018-2029)
Figure 74. Middle East, Africa and Latin America Angiogenesis Therapeutic Agent Revenue Market Share by Application (2018-2029)
Figure 75. Middle East, Africa and Latin America Angiogenesis Therapeutic Agent Revenue Share by Country (2018-2029)
Figure 76. Middle East, Africa and Latin America Angiogenesis Therapeutic Agent Sales Share by Country (2018-2029)
Figure 77. Brazil Angiogenesis Therapeutic Agent Revenue (2018-2029) & (US$ Million)
Figure 78. Mexico Angiogenesis Therapeutic Agent Revenue (2018-2029) & (US$ Million)
Figure 79. Turkey Angiogenesis Therapeutic Agent Revenue (2018-2029) & (US$ Million)
Figure 80. Israel Angiogenesis Therapeutic Agent Revenue (2018-2029) & (US$ Million)
Figure 81. GCC Countries Angiogenesis Therapeutic Agent Revenue (2018-2029) & (US$ Million)
Figure 82. Angiogenesis Therapeutic Agent Value Chain
Figure 83. Angiogenesis Therapeutic Agent Production Process
Figure 84. Channels of Distribution
Figure 85. Distributors Profiles
Figure 86. Bottom-up and Top-down Approaches for This Report
Figure 87. Data Triangulation
Figure 88. Key Executives Interviewed